The prevalence of antibodies to human T lymphotropic virus type I (HTLV-I) was studied in patients with primary Sjogren's syndrome. Thirteen of 36 serum samples were positive by enzyme linked immunosorbent assay (ELISA) and particle agglutination assay for antibodies to HTLV-I and were confirmed by western blotting. 
The human T lymphotropic virus type I (HTLV-I) is a retrovirus associated aetiologically with adult T cell leukaemia' and HTLV-I associated myelopathy/tropical spastic paraparesis.2 3 Proviral DNA integration is monoclonal in adult T cell leukaemia4 but occurs at random in the peripheral blood mononuclear cells and cerebrospinal fluid cells of patients with HTLV-I associated myelopathy/tropical spastic paraparesis.5 6 Areas known to be endemic for HTLV-I include the Caribbean Islands7 and southwestern Japan.' 2 The Nagasaki prefecture, which is located in southwestern Japan, is one of the areas endemic for HTLV-I.
Sjogren's syndrome is an exocrinopathy of presumed autoimmune aetiology causing keratoconjunctivitis sicca or xerostomia, or both.8 9 The characteristic histological findings are sialadenitis with lymphocytic infiltration of the salivary and lachrymal glands and proliferating nests of epithelial cells. Although many aetiologies have been proposed, the pathogenesis of this syndrome has not been clarified. There has been great interest in the association between Sjogren's syndrome and retrovirus infection.'0 11 In fact, an association between Sjogren's syndrome and HTLV-I has been suggested indirectly by case reports of HTLV-I infected patients with tropical spastic paraparesis who developed features of Sjogren's syndrome. 2 Clinical features of Sjogren's syndrome have been found in intravenous drug abusers who are at high risk for HTLV-I infection. 3 An exocrinopathy resembling Sjogren's syndrome is reported to be produced in HTLV-I tax transgenic mice. '4 In addition to being seen in those infected with HTLV-I, the clinical symptoms and signs of Sjogren's syndrome have been seen in some patients infected with human immunodeficiency virus (HIV-I). [5] [6] [7] In this study, we found that antibodies to HTLV-I are present in patients with primary Sjogren's syndrome and this paper presents in detail the clinical and laboratory features of primary Sjogren's syndrome which are associated with antibodies to HTLV-I.
Patients and methods

SUBJECTS
The experimental group included 36 patients with primary Sjogren's syndrome (two men and 34 women; mean (SD) age 52-6 (10-5) years, range ). The patients with Sjogren's syndrome attended the outpatient clinic of Nagasaki University School of Medicine. Sjogren's syndrome was diagnosed by the presence of objective evidence of lachrymal or salivary gland involvement, or both, as confirmed by Schirmer's test, sialography, or a minor salivary gland biopsy. Rheumatoid arthritis, systemic lupus erythematosus, and progressive systemic sclerosis were ruled out in each patient. Three of the 36 patients had been treated with prednisolone (less than 10 mg/day) and no other patient was receiving any systemic drugs. Carriers were defined as those who had antibodies to HTLV-I.
Two hundred and forty outpatients (36 men and 204 women; mean (SD) age 46-7 (10-3) years) in our hospital served as control subjects.
We studied immunologically 10 normal subjects with antibodies to HTLV-I (one man and nine women; mean (SD) age 39-6 (13-4) years) and 10 normal subjects without these antibodies (one man and nine women; mean (SD) age 48-5 (12-4) years).
CLINICAL LABORATORY DATA Antinuclear antibodies were detected by an indirect immunofluorescence procedure using HEp-2 cells. Antibodies to SS-A (Ro) and SS-B (La) antigens were determined by gel double immunodiffusion using rabbit thymus extract.
Antibodies to HTLV-I were measured by an enzyme linked immunosorbent assay (ELISA; Eitest-ATL kit, Eisai Inc, Japan) and the particle agglutination assay (Serodia-ATL kit, Fujirebio Inc, Japan). Western blot analysis was performed using HTLV-I antigens derived from the MT-2 cell line. ' 
Results
CLINICAL FEATURES OF HTLV-I SEROPOSITIVE PATIENTS
Thirteen of 36 patients with primary Sjogren's syndrome studied were positive for antibodies to HTLV-I (tables 1 and 2). In the western blot assay, all 13 serum samples reacted with HTLV-I gag (pl9, p24, and p28) and with HTLV-I env (gp68) (fig 1) . One patient was male and 12 female (mean (SD) age 51-7 (9 6) years). The mean (SD) age at the onset of clinical symptoms was 41-9 (9-8) years. The Nagasaki area was tentatively subdivided into the superendemic (first) and endemic (second) areas depending on the prevalence of antibodies to HTLV-I in subjects aged 40 years or more. All seropositive patients were born and had lived in the endemic (second) area. Antibodies to HTLV-I were also assayed in 240 age and sex matched control serum samples in our hospital. Positive serum samples were found in 15 (6%) subjects. One woman had high fever, joint pain, uveitis, xerophthalmia, and xerostomia. Her father and uncle had died of adult T cell leukaemia and her son, who had antibodies to
Sjdgren's syndrome with antibodies to HTLV-I bodies and antibodies to SS-B (La) in patients who had antibodies to HTLV-I were less than those in patients who did not have these antibodies, but this difference was not significant.
PROLIFERATIVE RESPONSES OF PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS WITH SJOGREN'S SYNDROME WITH OR WITHOUT ANTIBODIES TO HTLV-I
The mononuclear cells isolated from peripheral blood were cultured with or without mitogens (fig 2 and table 4) . Spontaneous proliferation of mononuclear cells from patients who were positive for these antibodies was markedly increased compared with that from patients who were negative for these antibodies. Furthermore, the spontaneous proliferation of mononuclear cells from normal subjects who were positive for these antibodies was significantly increased compared with that from normal subjects who were negative. Subjects who had antibodies to HTLV-I and those who did not had normal [3H]thymidine incorporation by their mononuclear cells in response to phytohaemagglutinin, concanavalin A, and pokeweed mitogen. As those patients with antibodies to HTLV-I had an increase in spontaneous mononuclear cell proliferation, the stimulation indices of mononuclear cells from patients with antibodies to HTLV-I responding to these mitogens were significantly less than those of cells from patients without these antibodies.
ACTIVATED T CELLS IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SJOGREN'S SYNDROME WITH OR WITHOUT ANTIBODIES TO HTLV-I
There was no significant difference in the percentage of CD3+ cells among patients who had antibodies to HTLV-I, those who did not, and normal subjects. Patients with Sjogren's syndrome had higher percentages of HLA-DR+ T cells and CD26+ T cells than normal subjects. Furthermore, patients with antibodies to HTLV-I had a significantly higher percentage of HLA-DR+ T cells compared with those without the antibodies ( fig 3A) . In addition, patients with antibodies to HTLV-I had a markedly higher percentage of CD25+ T cells than patients without the antibodies (fig 3B) . 
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group.bmj.com on April 20, 2017 -Published by http://ard.bmj.com/ Downloaded from and that in a third area which excludes Nagasaki is less than 5%. Furthermore, 15/240 (6%) serum samples from outpatients in our hospital were positive for antibodies to HTLV-I. Thirteen of the 36 patients had serum samples which were positive by ELISA and the particle agglutination assay for antibodies to HTLV-I and were confirmed to be positive by western blotting. We found antibodies to HTLV-I in none of seven patients with primary Sjogren's syndrome who were born in the first area, 13/26 (50%) patients who were born in the second area, and none of three patients who were born in the third area.
A comparison of the clinical features of our seropositive and seronegative patients showed that extraglandular manifestations including uveitis, myopathy, and recurrent high fever were higher in seropositive than in seronegative patients. Patients with HTLV-I associated myelopathy/tropical spastic paraparesis are known to have rheumatic syndromes such as T lymphocyte alveolitis,12 [23] [24] [25] polyarthritis,26 polymyositis,27 and uveitis. 28 It is important that such rheumatic syndromes may be associated with HTLV-I infection. Vernant et al reported that all of five patients with HTLV-I associated tropical spastic paraparesis had lymphocytic alveolitis and Sjogren's syndrome was confirmed histologically.'2 Only one of the five patients had xerophthalmia and xerostomia. It has been reported that HTLV-I provirus DNA was detected in the alveolar lymphocytes of patients with tropical spastic paraparesis. 25 Patients with adult T cell leukaemia who presented with proliferative synovitis have also been described. 29 We reported previously that patients with rheumatoid arthritis had a high prevalence of antibodies to HTLV-I,30 and an HTLV-I infected T cell line established from mononuclear cells taken from the synovial fluid of a patient with polyarthritis had HTLV-I proviral DNA similar to that seen in patients with adult T cell leukaemia and HTLV-I associated myelopathy.3' Clinical features suggest that Sjogren's syndrome complications in seropositive patients with rheumatoid arthritis were higher than in seronegative patients.30 In this study, the prevalence of interstitial pulmonary fibrosis and polyarthritis was slightly increased in patients with antibodies to HTLV-I compared with patients without these antibodies. An increase of the serum creatine kinase level was observed in eight of 13 patients who had antibodies to HTLV-I but in only one of 23 patients who did not. All of the patients except one man had chronic or relapsing increases of their serum creatine kinase level (less than 250 IU/1) and could not be diagnosed as having polymyositis by needle electromyography or muscle biopsy, or both. One man had diffuse weakness of the proximal muscles of his hands and feet and was found to have polymyositis by taking a muscle biopsy sample. A case of polymyositis in a patient infected with HTLV-I and the human immunodeficiency virus (HIV) has been reported. 32 In this patient, HTLV-I nucleic acids and antigens were localised specifically to atrophic muscle fibres in regions of inflammation. There were myopathic changes and the HTLV-I tat protein had accumulated in the muscle, making it resemble the muscle of a transgenic mouse carrying the HTLV-I tax gene. 32 The striking degree of inflammation, however, was not seen in the transgenic mouse model. These results support strongly the belief that myopathy, with or without inflammation, is associated with HTLV-I infection.
Patients with uveitis are known to have a high prevalence of antibodies to HTLV-I. 28 Uveitis has been found in one patient with HTLV-I polymyositis.32 In our clinical study, uveitis was found in four of 13 seropositive patients but in none of 23 40 It is apparent that HTLV-I has a preferential tropism for CD4+ cells in vivo and has the capacity to induce interleukin 2 production and CD25 expression and to trigger T cell proliferation.4 '42 In particular, HTLV-I infected T cells synthesise the CD25 chain, which is probably induced by the tat-I gene product of the virus. Given these findings, it seems likely that the increase in the percentage of CD25+ T cells found in seropositive patients with Sjogren's syndrome may be induced not by Sjogren's syndrome but by HTLV-I infection.
The pathogenesis of HTLV-I associated Sjogren's syndrome is unknown. It is possible that a disease triggering virus infection results from HTLV-I induced immunosuppression. Other mechanisms may be direct slow virus infection of the salivary glands, a cytotoxic immune reaction against HTLV-I infected cells in the salivary glands, or a humoral autoimmune disorder in which HTLV-I infected salivary gland cells share common antigenic determinants. On the basis of the clinical features and laboratory data of our patients, we suggest that HTLV-I plays a part in the pathogenesis of a subset of cases of primary Sjogren's syndrome.
